INVO Bioscience, Inc. (INVO)
NASDAQ: INVO · IEX Real-Time Price · USD
0.925
-0.006 (-0.66%)
May 3, 2024, 4:00 PM EDT - Market closed
INVO Bioscience Revenue
In the year 2023, INVO Bioscience had annual revenue of $3.02M with 267.38% growth. Revenue in the quarter ending December 31, 2023 was $1.38M with 396.78% year-over-year growth.
Revenue (ttm)
$3.02M
Revenue Growth
+267.38%
P/S Ratio
0.84
Revenue / Employee
$120,823
Employees
25
Market Cap
2.54M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.02M | 2.20M | 267.38% |
| Dec 31, 2022 | 822.20K | -3.34M | -80.24% |
| Dec 31, 2021 | 4.16M | 3.12M | 301.06% |
| Dec 31, 2020 | 1.04M | -442.93K | -29.92% |
| Dec 31, 2019 | 1.48M | 985.84K | 199.41% |
| Dec 31, 2018 | 494.38K | 212.23K | 75.22% |
| Dec 31, 2017 | 282.15K | 231.24K | 454.30% |
| Dec 31, 2016 | 50.90K | 39.21K | 335.46% |
| Dec 31, 2015 | 11.69K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| cbdMD | 23.45M |
| Sonoma Pharmaceuticals | 12.31M |
| SCWorx | 3.92M |
| Helius Medical Technologies | 644.00K |
| FOXO Technologies | 453.00K |
| 60 Degrees Pharmaceuticals | 253.57K |
INVO News
- 17 days ago - INVO Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 5 months ago - NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal - PRNewsWire
- 5 months ago - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies - PRNewsWire
- 5 months ago - INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - PRNewsWire
- 6 months ago - INVO Reports Record Third Quarter 2023 Financial Results - PRNewsWire
- 6 months ago - NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger - PRNewsWire
- 6 months ago - INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants - PRNewsWire
- 6 months ago - INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVO - Business Wire